JP2008530050A5 - - Google Patents

Download PDF

Info

Publication number
JP2008530050A5
JP2008530050A5 JP2007554541A JP2007554541A JP2008530050A5 JP 2008530050 A5 JP2008530050 A5 JP 2008530050A5 JP 2007554541 A JP2007554541 A JP 2007554541A JP 2007554541 A JP2007554541 A JP 2007554541A JP 2008530050 A5 JP2008530050 A5 JP 2008530050A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
butanol
composition according
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007554541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530050A (ja
JP5072604B2 (ja
Filing date
Publication date
Priority claimed from EP05100942A external-priority patent/EP1690858B1/en
Application filed filed Critical
Publication of JP2008530050A publication Critical patent/JP2008530050A/ja
Publication of JP2008530050A5 publication Critical patent/JP2008530050A5/ja
Application granted granted Critical
Publication of JP5072604B2 publication Critical patent/JP5072604B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007554541A 2005-02-10 2006-02-06 1−[3−[3−(4−クロロフェニル)プロポキシ]プロピル]−ピペリジン一塩酸塩 Expired - Lifetime JP5072604B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100942.1 2005-02-10
EP05100942A EP1690858B1 (en) 2005-02-10 2005-02-10 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
PCT/EP2006/050703 WO2006084833A1 (en) 2005-02-10 2006-02-06 Monohydrochloride salt of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine

Publications (3)

Publication Number Publication Date
JP2008530050A JP2008530050A (ja) 2008-08-07
JP2008530050A5 true JP2008530050A5 (https=) 2009-04-02
JP5072604B2 JP5072604B2 (ja) 2012-11-14

Family

ID=34938687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007554541A Expired - Lifetime JP5072604B2 (ja) 2005-02-10 2006-02-06 1−[3−[3−(4−クロロフェニル)プロポキシ]プロピル]−ピペリジン一塩酸塩

Country Status (22)

Country Link
US (2) US8207197B2 (https=)
EP (2) EP1690858B1 (https=)
JP (1) JP5072604B2 (https=)
KR (1) KR101344271B1 (https=)
CN (1) CN101155793B (https=)
AR (1) AR054734A1 (https=)
AT (2) ATE391716T1 (https=)
CA (1) CA2597016C (https=)
CY (1) CY1108428T1 (https=)
DE (2) DE602005005941D1 (https=)
DK (1) DK1846384T3 (https=)
ES (1) ES2309948T3 (https=)
HR (1) HRP20080446T3 (https=)
ME (1) ME01103B (https=)
MX (1) MX2007009574A (https=)
PL (1) PL1846384T3 (https=)
PT (1) PT1846384E (https=)
RS (1) RS50624B (https=)
SI (1) SI1846384T1 (https=)
TW (1) TWI393711B (https=)
UY (1) UY29369A1 (https=)
WO (1) WO2006084833A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
BRPI1008020A2 (pt) 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
SG176735A1 (en) 2009-06-10 2012-01-30 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
MX2012002898A (es) 2009-09-11 2012-04-02 Sunovion Pharmaceuticals Inc Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
WO2014199935A1 (ja) * 2013-06-10 2014-12-18 株式会社エム・エス・エス 小胞体ストレスシグナルを抑制することによる,薬剤の副作用としての体重増加や肥満を防止するために用いられる肥満防止剤
CN103435575A (zh) * 2013-08-06 2013-12-11 中国人民解放军军事医学科学院毒物药物研究所 1-( 3-( 3-( 4-氯苯基)丙氧基)丙基)哌啶盐酸盐的制备方法
CN104447620B (zh) * 2014-11-28 2016-05-04 瑞阳制药有限公司 1-[3-[3-(4-氯苯基)丙氧基]丙基]-哌啶盐酸盐的制备方法
EP3239138A1 (en) 2016-04-25 2017-11-01 Sandoz Ag Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
WO2020092604A1 (en) * 2018-10-30 2020-05-07 Concert Pharmaceuticals, Inc. Deuterated pitolisant
IT201900013941A1 (it) 2019-08-05 2021-02-05 Procos Spa PROCESSO PER LA SINTESI DI PITOLISANT HCl
CN110804026B (zh) * 2019-11-18 2022-04-01 苏州永健生物医药有限公司 1- (3- (3-(4-氯苯基)丙氧基)丙基)哌啶盐酸盐的合成方法
US11945788B2 (en) 2021-06-07 2024-04-02 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
US11623920B2 (en) 2021-06-07 2023-04-11 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
EP4457219A4 (en) * 2021-12-29 2025-12-10 Biophore India Pharmaceuticals Pvt Ltd SOLID FORMS OF 1-3-[3-(4-CHLOROPHENYL)PROPOXY]PROPYL PIPERIDINE HYDROCHLORIDE AND THEIR PREPARATION PROCESS
US20250281475A1 (en) * 2022-05-04 2025-09-11 Msn Laboratories Private Limited, R & D Center A pharmaceutical composition of pitolisant hydrochloride and their process for the preparation
WO2024084379A1 (en) * 2022-10-17 2024-04-25 Biophore India Pharmaceuticals Pvt. Ltd A NOVEL PROCESS FOR THE PREPARATION OF AMORPHOUS SOLID DISPERSION OF 1-{3-[3-(4-CHLOROPHENYL) PROPOXY] PROPYL} PIPERIDINE, HYDROCHLORIDE WITH HYDROXYPROPYL BETA-CYCLODEXTRIN (HPβCD)
EP4374854A1 (en) * 2022-11-28 2024-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical mixture comprising amorphous pitolisant
EP4688166A1 (en) 2023-03-31 2026-02-11 BIOPROJET Pharma Polymorph form of pitolisant hydrochloride
WO2025082974A1 (en) 2023-10-16 2025-04-24 Bioprojet Pharma New formulations of pitolisant and methods of use
EP4681704A1 (en) 2024-07-18 2026-01-21 BIOPROJET Pharma New formulations of pitolisant
EP4732903A1 (en) * 2024-10-28 2026-04-29 BIOPROJET Pharma Co-crystals of pitolisant hydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications

Similar Documents

Publication Publication Date Title
JP2008530050A5 (https=)
US8148372B2 (en) Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286
CN100430394C (zh) N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用
JP5452594B2 (ja) アルキルチアゾールカルバメート誘導体、この調製、およびfaah酵素阻害剤としてのこの使用
CA2589133A1 (en) Quaternary ammonium salts as m3 antagonists
JP2007504114A (ja) 8−(1−ピペラジニル)キノリン誘導体およびcns疾患の治療におけるそれらの使用
CN114206836B (zh) 新型吡咯化合物
NZ251687A (en) Oxadiazol- and thiadiazol- phenylcarbamates and -phenylureas and pharmaceutical compositions thereof
US20100179118A1 (en) Cyclic aminoalkylcarboxamide derivative
JPWO1996029330A1 (ja) チアゾール誘導体
JP2016520636A (ja) トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
HK1053109B (zh) 取代的高哌啶基苯并咪唑化合物和含其的药物组合物以及其制法和制药用途
JPWO2000023436A1 (ja) キナゾリノン誘導体
JP4648544B2 (ja) (1−フェナシル−3−フェニル−3−ピペリジルエチル)ピペリジン誘導体、その製造方法およびそれを含有する医薬組成物
EP4688166A1 (en) Polymorph form of pitolisant hydrochloride
JP2002536442A5 (https=)
KR101070176B1 (ko) Cb1에 길항 활성을 갖는 1h-파이라졸-3-아마이드계 화합물 또는 1h-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물
WO2009110519A1 (ja) 新規1-アミノカルボニルピペリジン誘導体
EP2526100B1 (en) Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
HK40129301A (zh) 盐酸替洛利生的多晶型形式
WO2000078758A1 (en) Novel imidazole derivatives
HK1155744B (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
JP2011530589A (ja) 4−(5−{(1r)−1−[5−(3−クロロフェニル)イソオキサゾール−3−イル]エトキシ}−4−メチル−4h−1,2,4−トリアゾール−3−イル)ピリジンの新規な結晶形態
JPWO1998012195A1 (ja) 2−カルボニルチアゾール誘導体及びその用途